Full-Time

Senior Medical Writer

Updated on 8/3/2026

MMS

MMS

1,001-5,000 employees

Regulatory compliance and data solutions provider

No salary listed

Canton, MI, USA

Remote

Bachelor's, Master's, PhD

Category
Content & Writing (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets

Get referred to MMS

See people who can refer or advise you

Requirements
  • At least 3 years of previous experience in the pharmaceutical industry.
  • At least 3–5 years of industry regulatory writing and clinical medical writing experience.
  • A Bachelor's, Master's, or Ph.D. degree in a scientific, medical, or clinical discipline is ideal.
  • Substantial clinical study protocol experience as lead author.
  • Experience leading and managing teams while authoring regulatory documents with aggressive timelines.
  • Understanding of clinical data.
  • Exceptional writing skills.
  • Strong organizational skills and the ability to multitask.
  • Expertise in Microsoft Word, Excel, PowerPoint, and related word-processing tools.
  • Experience as a project lead or managing a project team.
Responsibilities
  • Critically evaluate, analyze, and interpret medical literature to select primary resource materials based on adequate study design, statistical significance, scientific rigor, and absence of bias.
  • Write and edit clinical development documents, including clinical protocols, investigator brochures, clinical study reports, subject consent forms, integrated safety and efficacy summaries, Modules 2.7.1, 2.7.2, 2.7.3, 2.7.4, and 2.5 documents, presentation materials, and medical-journal publications.
  • Complete writing assignments in a timely manner.
  • Maintain timelines and workflow for writing assignments.
  • Provide internal and external customer service.
  • Apply writing styles for various regulatory documents.
  • Use client templates and style guides.
  • Interact directly and independently with clients to coordinate all facets of projects.
  • Contribute substantially to, or manage, production of interpretive guides.
  • Take ownership of assignments and consult project team members and department representatives for information or guidance as needed.
  • Mentor medical writers and other project team members involved in the writing process.
Desired Qualifications
  • Experience with regulatory submissions, including clinical study reports presented to regulatory authorities.
  • Understanding of federal regulations, Good Clinical Practices, and International Council for Harmonisation guidelines.
  • Experience with orphan drug designations and PSP/PIPs.

MMS Holdings is a global contract research organization (CRO) focused on regulatory compliance and data-driven solutions for pharmaceutical and biotech sponsors. It delivers services such as regulatory submissions, clinical trial management, data analytics, and medical writing through a service-based model that relies on established processes and experienced advisors. Its work is contract-based, often long-term, aimed at helping clients meet regulatory requirements, run trials efficiently, and advance therapies under FDA guidance. The company differentiates itself with a science-first approach, a strong track record (97% client satisfaction), and involvement in complex areas like enabling MDMA-assisted therapy research, underscoring a commitment to high-quality, compliant outcomes for sponsors globally.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Canton, Ohio

Founded

2006

Get referred to MMS

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Datacise reached ACDM finalist status in January 2026, validating MMS's software strategy.
  • West Coast expansion before BIO 2026 targets venture-backed biotechs and faster sponsor acquisition.
  • I-ACT and pediatric-trials partnerships broaden MMS's therapeutic footprint and referral network.

What critics are saying

  • MMS still depends on sponsor-funded biotech budgets; trial delays hit revenue fast in 2026.
  • Private-equity ownership under Lindsay Goldberg pushes margin discipline before culture and retention.
  • Ascendancy in biometrics invites competition from IQVIA, Parexel, and Medidata on bigger accounts.

What makes MMS unique

  • Exploristics acquisition added KerusCloud and deep biostatistics, strengthening MMS's data science edge.
  • Ben Dudley became President in May 2026, sharpening global commercial and scientific execution.
  • Former FDA leaders Somya Dunn and other advisors deepen MMS's regulatory credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

20%

1 year growth

20%

2 year growth

20%
MMS Holdings
Feb 12th, 2025
MMS Acquires Exploristics for Data Science Expansion

MMS, a clinical research organization, has acquired Exploristics, a biostatistics and data science company. This acquisition enhances MMS' capabilities in advanced clinical trial design and data science, integrating Exploristics' KerusCloud® platform. The move expands MMS' global presence, particularly in Europe, and aims to optimize drug development strategies, reducing time and costs. Exploristics' CEO, Aiden Flynn, joins MMS as Senior VP, Head of Strategic Statistical Consulting.

TipRanks
Jan 29th, 2024
Orgenesis Inc Strikes Definitive Deal to Acquire Octomera LLC

On January 29, 2024, Orgenesis Inc. acquired all equity interests in Octomera LLC from MM OS Holdings, L.P., an affiliate of Metalmark Capital.

MMS Holdings
Apr 18th, 2023
MMS Named Great Place To Work In The UK

MMS Holdings Inc. plan to expand and grow in the UK and Europe to build on its teams and deliver value to its clients”

Applied Clinical Trials
Apr 14th, 2023
People and Business News – 4/23

EmVenio Research announced the appointment of Mark Mackenzie, MD, as chief medical officer.

Business Wire
Mar 21st, 2023
MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise | Business Wire

MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.